Fennec Pharmaceuticals Inc. (FENNC) is a respected biopharmaceutical company that specializes in advancing treatments for cancer and other significant unmet medical needs. FENNC is dedicated to a relentless pursuit of efficiency and innovation in improving the quality of life and long-term outcomes of patients worldwide. Beyond its commitment to research and development, the company seeks to create value by leveraging its experience and capabilities to develop a portfolio of innovative products to address the needs of patients.
Established in 2003, the company, formerly known as Adherex Technologies Inc., changed its name to Fennec Pharmaceuticals Inc. in September 2014. The decision to change the company name reflected a broader restructuring plan to more effectively align the company's brand with its core mission of patient-focused pharmaceutical innovation. Headquartered in Research Triangle Park in North Carolina, USA, and with an additional office in Ontario, Canada, Fennec Pharmaceuticals operates at the cutting edge of biotechnological advances.
Fennec Pharmaceuticals Inc's flagship product is PEDMARK (a unique formulation of Sodium Thiosulfate). PEDMARK has demonstrated compelling efficacy in reducing ototoxicity (ear toxicity) caused by cisplatin in a pivotal Phase 3 clinical study in children. Cisplatin is a potent chemotherapy drug used in numerous pediatric malignancies; however, it can cause severe problems, including hearing loss. By addressing this significant unmet need, the company aims to substantially improve these patients' quality of life.
Following the successful outcome of the Phase 3 clinical trials for PEDMARK, Fennec Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 2020, seeking approval for the drug's use in preventing cisplatin-related ototoxicity in pediatric patients. This submission marked an important milestone in the company's history.
Equipped with its promising drug portfolio coupled with the dedication of its competent team and strategic collaborations, Fennec Pharmaceuticals Inc continues to maintain its competitive edge while contributing significantly to the field of medicine. The company is dedicated to achieving distinct advances in care for patients who have limited or inadequate treatment options. The leadership at FENNC is persistently focused on enhancing shareholder value while taking steps toward the attainment of important goals in transformative health care. Their unwavering commitment to innovation and quality care makes Fennec Pharmaceuticals a shining star in the biopharmaceutical industry.